Related Experiment Video
Updated: Jan 29, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Immune Dysregulation and Cytokine Profiling in Acute Mycoplasma pneumoniae Pneumonia
Ying Wen1,2, Yanfang Zhai2, Shuli Sang2
1School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Abstract:
Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection characterized by significant inflammatory responses and lung tissue injury. However, the precise immunological mechanisms and temporal dynamics of key cytokines driving pulmonary inflammation in MPP are still unclear. This study aimed to investigate the underlying immunological mechanisms and cytokine dynamics in MPP. We established an acute MPP murine model via intranasal administration of M. pneumoniae. This model recapitulates key features of human MPP, such as robust airway inflammation and cytokine production. Comprehensive analyses were conducted, including histopathology, flow cytometry, and cytokine profiling. Results showed severe inflammatory responses with prominent infiltration of neutrophils and macrophages in lung tissue, whereas monocyte populations were significantly reduced, indicating a shift towards myeloid cell predominance. Notably, 36 cytokines, including pro-inflammatory interleukins (IL-1β, IL-6, IL-17A) and chemokines, were statistically significantly upregulated in bronchoalveolar lavage fluid compared to the normal group, highlighting a cytokine storm associated with lung inflammation and tissue damage. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway analysis further revealed enriched pathways related to cytokine-cytokine receptor interactions and IL-17 signaling, suggesting potential therapeutic targets. In conclusion, this study preclinical provides insights into the innate immune response and cytokine-driven pathology in acute MPP, underscoring the pivotal roles of myeloid cells and pro-inflammatory cytokines. Future research should focus on clinical validation of these findings to assess their translational potential and the exploration of immunomodulatory strategies informed by this model to mitigate MPP severity.
Insights
This study reveals that Mycoplasma pneumoniae pneumonia (MPP) causes significant lung inflammation by increasing myeloid cells and a cytokine storm, involving key interleukins like IL-6 and IL-17A.
Area of Science:
- Immunology
- Pulmonology
- Microbiology
Background:
- Mycoplasma pneumoniae pneumonia (MPP) causes lung injury and inflammation, but its precise immune mechanisms and cytokine dynamics remain unclear.
- Understanding these processes is crucial for developing effective treatments for MPP.
Purpose of the Study:
- To investigate the immunological mechanisms and cytokine dynamics in an acute MPP murine model.
- To identify key cellular players and signaling pathways involved in MPP pathogenesis.
Main Methods:
- Established an acute MPP murine model using intranasal M. pneumoniae administration.
- Performed histopathology, flow cytometry, and cytokine profiling on bronchoalveolar lavage fluid.
- Utilized Gene Ontology and KEGG pathway analysis to identify enriched signaling pathways.
Main Results:
- Observed severe airway inflammation with neutrophil and macrophage infiltration, and reduced monocyte populations.
- Identified significant upregulation of 36 cytokines, including IL-1β, IL-6, and IL-17A, indicating a cytokine storm.
- Enriched pathways included cytokine-cytokine receptor interactions and IL-17 signaling.
Conclusions:
- Acute MPP involves a strong innate immune response dominated by myeloid cells and a pro-inflammatory cytokine storm.
- Identified key cytokines and pathways that may serve as therapeutic targets for mitigating MPP severity.
- Preclinical findings highlight the need for clinical validation and exploration of immunomodulatory strategies.
More Related Videos
09:49Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
What is the Immune System?